SFM
DSGN icon

Sphera Funds Management’s Design Therapeutics DSGN Stock Holding History

Sphera Funds Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-21,918
Closed -$165K – 109
2025
Q3 		$165K Buy
+21,918
New +$110K 0.03% 111

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Sphera Funds Management's DSGN Position: Q4 2025 in Review

Sphera Funds Management sold out of Design Therapeutics (DSGN) in Q4 2025, closing a stake of 21,918 shares — an estimated $165K sold.

Sphera Funds Management first reported a position in DSGN in Q3 2025 and held it in 1 quarter. The position peaked at $165K in Q3 2025. 117 funds tracked by Wall St. Rank hold DSGN as of Q4 2025.

  • Sphera Funds Management reported no remaining Design Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Sphera Funds Management sold 21,918 Design Therapeutics shares in Q4 2025, an estimated $165K.
  • Sphera Funds Management first reported a position in Design Therapeutics in Q3 2025 and held it in 1 quarter.
  • Sphera Funds Management's Design Therapeutics position peaked at $165K in Q3 2025.
  • 117 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2025.

Based on Sphera Funds Management's 13F filing for Q4 2025, filed 17 Feb 2026.